Drug Conjugate Manufacturers, Suppliers & Companies
-
Manufacturerbased in Oss, NETHERLANDS
Founded in 2010, Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business ...
GlycoConnect - Model ADC - Antibody-Drug Conjugation
Any antibody can be converted into a stably conjugated ADC in just a few days by modifying the native antibody glycan using our highly efficient enzymes and metal-free click chemistry approach. Multiple independent experiments ...
CONTACT SUPPLIER -
Manufacturerbased in Redmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
SystImmune - Model BL-M11D1-ADC - Antibody Drug Conjugates (ADC) Molecules
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s ...
CONTACT SUPPLIER -
Manufacturerbased in Au, Zurich, SWITZERLAND
Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ ...
Araris - Antibody-Drug Conjugates (ADCs) Linker Technology
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform ...
CONTACT SUPPLIER -
Technologybased in Daejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
Antibody-Drug Conjugate - ADC
ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of ...
CONTACT SUPPLIER -
Manufacturerbased in Lyon, FRANCE
Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugates (ADCs). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the ...
Mablink - Antibody–Drug Conjugates (ADCs) Technology
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal ...
CONTACT SUPPLIER -
Manufacturerbased in Paoli, PENNSYLVANIA (USA)
MuseChem provides custom synthesis service related to compound chemicals, especially peptide synthesis, and analytical service. Our services help you faster drug discovery and better bio-medical research. MuseChem is your reliable partner for ...
Antibody-Drug Conjugates (ADCs) Services
Antibody-drug conjugates (ADCs) are a new class of highly potent oncology therapeutics for the treatment of people with cancer. An ADC could be divided into three main structural units: the antibody; the cytotoxic ...
CONTACT SUPPLIER -
Manufacturerbased in South San Francisco, CALIFORNIA (USA)
Fostering a culture grounded in our vision, mission and values, CytomX is an Xtraordinary clinical-stage biopharmaceutical company with a unique approach to treating cancer and a team dedicated to make a difference. We call this the CytomX Factor. ...
CytomX - Model CX-2009 - CD166 - Probody Drug Conjugate (PDC)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely ...
CONTACT SUPPLIER -
Technologybased in Carmel, INDIANA (USA)
Sword Diagnostics is a cutting-edge life sciences company created in response to the rapidly evolving needs of the research and pharmaceutical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and ...
Antibody-Drug Conjugates (ADC)
Sword scientists will use our cell-based assay development expertise to develop a customized method to corroborate the binding specificity of your antibody-drug conjugate (ADC). Our understanding of the molecular ...
CONTACT SUPPLIER -
Technologybased in Melbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
Starpharma - Antibody Drug Conjugates
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ...
CONTACT SUPPLIER -
Manufacturerbased in Florence, ITALY
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, ...
Model MEN1309 - Antibody-Drug Conjugate (ADC)
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its ...
CONTACT SUPPLIER -
Technologybased in Bubendorf, SWITZERLAND
CIS Pharma is an innovator in the life science industry in the field of Oncology and Ophthalmolog. We were awarded with the European Frost & Sullivan Technology Innovation Award for our unique smart polymer technologyœ, says Christoph Schäfer, CEO ...
CIS Pharma - Novel Antibody Drug Conjugates (ADCs)
CIS Pharma develops novel antibody-drug- conjugates (ADCs) based on our proprietary polymer carrier platform. Our polymers serve as carriers that are loaded with cytotoxic drugs, radioisotopes or ...
CONTACT SUPPLIER -
Manufacturerbased in Munich, GERMANY
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of protein-drug conjugates by ...
-
Technologybased in Vancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a ...
CONTACT SUPPLIER -
Manufacturerbased in Somerset, NEW JERSEY (USA)
As the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, we conduct all our business responsibly and with integrity. Our ...
SMARTag - Antibody-drug Conjugates (ADCs) & Bioconjugates Technology
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via ...
CONTACT SUPPLIER -
Technologybased in South San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro - iADCs and Antibody-Drug Conjugates
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
CONTACT SUPPLIER -
Manufacturerbased in New Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
EirGenix - Model TSY0110 (EG12043) - Antibody-Drug Conjugate
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
CONTACT SUPPLIER -
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Dolaflexin
The Dolaflexin platform was designed to increase the efficacy, safety, and tolerability of ADCs. This platform overcomes the limitations of traditional ADCs in which drugs are directly conjugated to antibodies. ...
CONTACT SUPPLIER -
Manufacturerbased in Barbengo – Lugano, SWITZERLAND
With over 40 years in the pharmaceutical industry, Cerbios is a privately held company with headquarter in Barbengo-Lugano, Switzerland, specialising in the development and manufacture of both chemical and biological APIs for its partners worldwide. ...
-
Manufacturerbased in Aberdeen, CHINA
Over the last 10 years, Creative Biolabs has become a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world. Creative Biolabs was founded by ...
Conjugate Sites Analysis
Antibody-drug conjugates employ the specific monoclonal antibodies (mAbs) to achieve targeted delivery of the conjugated cytotoxic molecules to tumor cells. This delicate design increases the ...
CONTACT SUPPLIER -
Manufacturerbased in Oxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
GlyMab - Model Anti-glycan mAb - Antibodies for Cancer
interactions through modulation of adhesion and cell trafficking. Glycosylation is increasingly recognised as a modulator of the malignant phenotype of cancer cells, where the interaction between cells and the tumour micro-environment is altered to ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you